Name: UMIN ID:
Unique ID issued by UMIN | UMIN000026004 |
---|---|
Receipt number | R000029850 |
Scientific Title | Safety evaluation study about rituximab therapy for refractory pemphigus |
Date of disclosure of the study information | 2017/03/08 |
Last modified on | 2021/03/04 18:59:20 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2017/02/04 16:56:39 | ||
2 | Update | 2017/02/04 17:04:14 | Name of secondary funder(s) Name of secondary funder(s) |
|
3 | Update | 2017/03/08 17:05:58 | Key secondary outcomes Key secondary outcomes |
|
4 | Update | 2017/03/08 17:08:06 | Date of disclosure of the study information |
|
5 | Update | 2017/03/08 17:17:49 | Public title |
|
6 | Update | 2017/05/05 09:28:06 | Public title |
|
7 | Update | 2017/05/05 09:31:24 | Key exclusion criteria Key exclusion criteria |
|
8 | Update | 2017/05/05 09:34:22 | Recruitment status Anticipated trial start date |
|
9 | Update | 2018/08/07 13:23:48 | Last name of contact person Last name of contact person Name of person sending information Name of person sending information |
|
10 | Update | 2021/03/04 18:45:41 | Target sample size |
|
11 | Update | 2021/03/04 18:52:35 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Name of person sending information Name of person sending information Organization1 Tel1 Organization Organization Address Address Tel Secondary IDs Study ID_1 Org. issuing International ID_1 Org. issuing International ID_1 |
|
12 | Update | 2021/03/04 18:59:20 | Date of IRB Anticipated trial start date Last follow-up date |